Clinical Trial Update: Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial in China is evaluating BCMA-CART with or without autologous stem cell transplant in young patients with multiple myeloma, currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA-CART (BCMA-targeted chimeric antigen receptor T cell therapy)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING